vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
21.60
-0.95 (-4.21%)
At close: Oct 8, 2025, 4:00 PM EDT
21.72
+0.12 (0.56%)
After-hours: Oct 8, 2025, 4:04 PM EDT
vTv Therapeutics Employees
vTv Therapeutics had 23 employees as of December 31, 2024. The number of employees increased by 7 or 43.75% compared to the previous year.
Employees
23
Change (1Y)
7
Growth (1Y)
43.75%
Revenue / Employee
$739
Profits / Employee
-$850,217
Market Cap
158.49M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23 | 7 | 43.75% |
| Dec 31, 2023 | 16 | 3 | 23.08% |
| Dec 31, 2022 | 13 | 4 | 44.44% |
| Dec 31, 2021 | 9 | -16 | -64.00% |
| Dec 31, 2020 | 25 | -1 | -3.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VTVT News
- 23 days ago - vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting - GlobeNewsWire
- 5 weeks ago - UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 5 weeks ago - vTv Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 5 weeks ago - vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund - GlobeNewsWire
- 2 months ago - vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin - GlobeNewsWire
- 2 months ago - vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes - GlobeNewsWire
- 4 months ago - vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series - GlobeNewsWire